Submission Details
| 510(k) Number | K192239 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | August 19, 2019 |
| Decision Date | October 17, 2019 |
| Days to Decision | 59 days |
| Submission Type | Traditional |
| Review Panel | Cardiovascular (CV) |
| Summary | Summary PDF |
K192239 is an FDA 510(k) clearance for the WavelinQ Plus EndoAVF System, a Percutaneous Catheter For Creation Of An Arteriovenous Fistula For Hemodialysis Access (Class II — Special Controls, product code PQK), submitted by C.R. Bard, Inc. (Tempe, US). The FDA issued a Cleared decision on October 17, 2019, 59 days after receiving the submission on August 19, 2019. This device falls under the Cardiovascular review panel. Regulated under 21 CFR 870.1252.
| 510(k) Number | K192239 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | August 19, 2019 |
| Decision Date | October 17, 2019 |
| Days to Decision | 59 days |
| Submission Type | Traditional |
| Review Panel | Cardiovascular (CV) |
| Summary | Summary PDF |
| Product Code | PQK — Percutaneous Catheter For Creation Of An Arteriovenous Fistula For Hemodialysis Access |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 870.1252 |
| Definition | Percutaneous Catheter For Creation Of An Arteriovenous Fistula For Hemodialysis Access. This Device Is A Single Use Percutaneous Catheter System That Creates An Arteriovenous Fistula In The Arm Of Patients With Chronic Kidney Disease Who Need Hemodialysis. |